Retroviral vectors have been widely used in human gene therapy protocols. Entry into target cells is directed
In recent years, extensive efforts have been made to develop retroviral vectors for gene therapy that can target specific cell types (5, 6, 13, 19, 28, 29) . Retroviral envelope proteins have been engineered to contain ligands or single-chain antibodies that redirect virus binding and tropism. However, to obtain a functional envelope protein and to achieve gene delivery, it has often been necessary to coexpress the wild-type envelope protein (5, 13, 19, 29) . Complementation between the defective targeting envelope protein and the wild-type envelope protein can be envisioned at various levels, from assistance with the processing and cell surface transport of the chimeric molecules as part of an envelope protein oligomer to the more intriguing possibility that binding and postbinding functions can be functionally separated between two different envelope protein monomers. The goal of the present study was to address these possibilities.
The envelope protein of Moloney murine leukemia virus (MoMuLV) plays an essential role in receptor-mediated virus binding, fusion, and entry (31) . The protein is initially translated as a precursor, Pr85, and then is assembled as an oligomer in the endoplasmic reticulum (ER) (7, 11, 18) . Oligomerized protein is transported to the Golgi compartment, where it is proteolytically cleaved into two subunits, surface protein (SU; gp70) and transmembrane protein (TM; p15E) by a cellular protease. At the time of virus budding or shortly thereafter, p15E is further processed by the viral protease to release a 16-amino-acid peptide (R-peptide) from the carboxyl terminus of p15E. The p15E and the processed p12E forms of TM coexist in the mature virion (12) .
Several studies have shown that binding to the host cell receptor is a property of the SU subunit (1, 2, 14, 22) . For MoMuLV, we have previously identified critical residues in a cysteine-constrained loop of SU that are required for interaction with the ecotropic receptor, notably amino acid D84 (20) . The postbinding functions of the envelope protein that lead to fusion between the virion and cellular membranes and allow core entry are largely a property of the TM subunit (32) .
Current models of retroviral entry predict that following the interaction of the SU subunit with its receptor, a conformational change is triggered in the associated TM subunit that leads to the adoption of a fusogenic conformation, in a manner analogous to influenza virus HA (3, 4) . The engineering of a retroviral envelope protein to alter its tropism requires that the interaction with the targeted cell surface molecule recapitulate this process, which may require both interactions between SU and TM within an envelope protein monomer and the concerted action of several monomers within the envelope protein oligomer.
To investigate the interactions between the SU and TM subunits in the envelope protein oligomer, we sought to determine whether defective envelope proteins containing mutations in different subunits could functionally complement each other. Our data demonstrates that envelope protein defective in the SU binding domain can be functionally complemented by the coexpression of envelope proteins defective in TM fusion functions and that this complementation probably occurs in trans within an envelope protein heterooligomer.
MATERIALS AND METHODS
Envelope mutants. All the envelope protein point mutants were constructed in the ecotropic envelope protein expression vector CEE ϩ (20) with the oligonucleotide-directed in vitro mutagenesis system version 2.1 (Amersham, Arlington Heights, Ill.). The E/A mutant is a replacement of amino acids 46 to 96 of ecotropic envelope protein by amino acids 47 to 67 of amphotropic (4070A) envelope protein. Site-directed mutagenesis was performed on CEE ϩ with oligonucleotides GCAACACTGCCTGGAACAGGCTAAAGC and GGACCTG GTGGCCAGATCTTACC, to introduce unique EcoNI and BglII sites into the codon for the flanking amino acids 46 and 96 (plasmid CEE/BN) without affecting the amino acid sequence. The amphotropic envelope sequence was generated by PCR with primers that contain EcoNI and BglII sites (template, TGGCC AGATCTTACCCCAGATTTATGTGATCTGGTCGGAGAGGAGTGGGAC CCTTCAGACCAGGAACCGTATGTCGGGTATGGCTGCAACACTG CCTGGAACAGGCTCAAGC; PCR primer, GGACCTGGTGGCCAGATCT TACC and GTTGTCTGGTCTAGCTTGAGCCTGTTCCAGGCAGTGTTG CACC) and was inserted into CEE/BN to produce E/A.
Cell lines. NIH 3T3 cells, GPL cells (21) , and 293T cells were maintained in D10, Dulbecco's modified essential medium (Cell Culture Core Facility, University of Southern California) supplemented with 10% fetal calf serum (Hyclone, Logan, Utah) and 2 mM glutamine (Gibco-BRL, Grand Island, N.J.). GPL cells are an NIH 3T3-derived preproducer cell line expressing gag-pol of MoMuLV and the retroviral vector LNL6. XC cells were subcloned from the XC cell line to produce a clone that was hyperfusogenic (27a) and were maintained in basal medium Eagle (Gibco-BRL) supplemented with 10% fetal calf serum and 2 mM glutamine. were transfected with 15 g of envelope expression plasmid by the calcium phosphate procedure as described previously (21) . At 16 h after transfection, the precipitate was removed and replaced with D10 for 48 h, after which time the supernatant was harvested and filtered through a 0.45-m-pore-size filter. To measure the titer, 3 ϫ 10 4 NIH 3T3 cells were plated in a 30-mm well of a six-well tissue culture plate; 18 to 24 h later, the medium was replaced with 1 ml of serially diluted fresh viral supernatant containing Polybrene (8 g/ml), the mixture was incubated overnight, and the cells were selected for G418 resistance by growth for 10 days in D10 containing G418 (600 g/ml). G418-resistant colonies were counted after methylene blue staining.
Cell-cell fusion assay. The XC cell fusion assay, used to characterize envelope protein fusion ability, has been described previously (21) . To measure syncytium formation on NIH 3T3 cells and GPL cells, 2 ϫ 10 5 cells were plated on a 60-mm tissue culture dish and envelope protein expression plasmids were transfected. The precipitate was replaced with fresh D10, and the plates were stained with methylene blue. Cells with more than four nuclei were scored as syncytia under the microscope.
Coimmunoprecipitation. Envelope protein plasmid was transfected into 293T cells by the calcium phosphate procedure. After 16 h, the suspension of precipitate was replaced with D10 containing 10 mM sodium butyrate (Sigma, St. Louis, Mo.). At 12 h later, the D10-sodium butyrate was removed and the cells were washed with Dulbecco's phosphate-buffered saline (Gibco-BRL) and incubated for 1 h at 37°C with cell-labeling medium (Dulbecco's modified essential medium without methionine and cysteine but with 10% dialyzed fetal bovine serum . The samples were incubated overnight at 4°C, and the pellet was washed three times with the immunoprecipitation buffer. The pellet was resuspended in 2 ϫ sodium dodecyl sulfate (SDS) gel-loading buffer (Novex, San Diego, Calif.) with 10% 2-mercaptoethanol and boiled for 5 min. The supernatant, after a brief centrifugation, was loaded on an 8 to 16% polyacrylamide gel and electrophoresed. The gel was fixed in 5% acetic acid-5% isopropanol, washed in water, and then soaked in Autofluor (National Diagnostics, Atlanta, Ga.) to enhance the signal. The dried gel was exposed to BioMax MR film (Eastman Kodak, Rochester, N.Y.) at Ϫ70°C overnight.
For the pulse-chase labeling study, at 24 h after transfection the cells were starved for 1 h in labeling medium and then incubated for 30 min in labeling medium containing 100 Ci each of [
35 S]methionine and [ 35 S]cysteine. The cells were washed three times with cold Dulbecco's phosphate-buffered saline, changed to regular D10 supplemented with 1 mM methionine and 2.5 mM cysteine, and incubated at 37°C for different periods. The cells were lysed and immunoprecipitated with goat anti-gp70 antiserum as described previously (20) .
RESULTS
Properties of envelope protein mutants. Two classes of MoMuLV envelope protein mutants were used in this study, a binding-defective SU mutant D84K (20) and several fusiondefective TM mutants (Fig. 1) . The mutations in the TM mutants are located in three separate regions of p15E and include a point mutation (T461P) near the N-terminal fusion peptide region, two substitutions (L493V and L493R) within a putative heptad repeat region, and a deletion in the cytoplasmic tail of the protein (dl603-606) (15) . All of these mutations primarily affect the postbinding events leading to fusion. Similar mutants have been described by others (16, 26) . Another SU mutant used in this study, E/A, which has 51 amino acid residues of the ecotropic envelope binding domain (amino acids 46 to 96) replaced by a 21-amino-acid stretch from an analogous region of the amphotropic (4070A) envelope protein (amino acids 47 to 67), is a transport-defective mutant, as demonstrated in Fig.  2 by a pulse-chase labeling assay. The gp70 from the E/A construct cannot be detected in the supernatant by immunoprecipitation after 2 h of chase (Fig. 2B) , and only a weak signal appears after 6 h of chase ( Fig. 2B and C) . We also could not detect gp70 of E/A on the cell surface by immunofluorescence analysis (data not shown). The properties of the mutants used in the study are summarized in 3 and 6) . This is because the wild-type env protein has been transported to the Golgi and has been glycosylated whereas the E/A env protein is still in the ER.
the cotransfection of D84K with each of the defective TM mutants resulted in viral particles that were able to transduce NIH 3T3 cells. Presumably, the receptor binding function absent from the D84K mutant protein was provided by the wildtype SU domain of the TM mutants, while the D84K mutant contributed the postbinding functions that reside in its normal TM subunit. Although all of the fusion mutants we examined thus far can complement the binding mutants, clearly there are going to be fusion mutants that cannot do so.
We also repeated these analyses with a transport defective SU mutant, E/A. When E/A was coexpressed with the TM mutants used in this study, complementation for transduction was observed, although less efficiently than with the simple point mutant D84K ( Table 2 ). The partial rescue of the transport-defective mutant E/A by the TM mutants suggests that complementation between defective proteins can occur as early as in the ER, where envelope protein oligomers form.
Envelope protein-mediated cell-cell fusion. Further evidence for the complementation between functional binding and functional fusion domains within the same heterooligomer is provided by the following experimental approaches. We used the phenotype of the R-peptide-truncated (R-less) form of the envelope protein. The expression of wild-type envelope protein results in syncytium formation in XC cells but not in NIH 3T3 or GPL cells. However, expression of the R-less form of the wild-type envelope protein will cause extensive syncytium formation in both NIH 3T3 and GPL cells (25, 27) . We constructed the mutant D84KTR, which is D84K with the cytoplasmic tail truncated at the normal R-peptide cleavage site. The coexpression of D84KTR with wild-type envelope protein caused extensive syncytium formation similar to that seen with wild-type R-less envelope protein ( Fig. 3; Table 3 ), indicating that the R-less phenotype is active in trans. The transfection of D84KTR alone into NIH 3T3 or GPL cells did not induce syncytium formation, a result that was expected because of the binding-defective phenotype of this mutant (Table 1) . However, the cotransfection of D84KTR with any of the TM mutants resulted in syncytium formation in both NIH 3T3 and GPL cells (Fig. 3 and data not shown) .
Heterooligomers are formed between SU and TM mutants. The above experiments demonstrated that SU and TM defective mutants can complement in trans for both transduction and cell-cell fusion. It is possible that this complementation is occurring solely within a heterooligomer or, instead, between homooligomers. Although our data cannot definitively distinguish between these two possibilities, we could confirm that heterooligomers do indeed form on the viral surface. An antiserum to R-peptide can immunoprecipitate the R-less form of TM (p12E), in addition to the full-length form of TM (p15E), when both full-length and R-less forms of the wildtype envelope are coexpressed in 293T cells. The absence of the viral proteinase means that the R-peptide will not be cleaved from the full-length protein, so that the presence of p12E in the precipitate is the result of an interaction between the p15E and p12E molecules. This hypothesis is supported by the results of control experiments in which lysates from cells transfected separately with a full-length form (CEE ϩ or L493V) and an R-less form (CEETR or D84KTR) of the proteins were mixed and only full-length protein was immunoprecipitated by the anti-R-peptide antiserum, thereby suggesting that the immunoprecipitation of p12E by the antiserum required a mixed envelope heterooligomer (data not shown).
We used this observation to confirm that heterooligomers do indeed form between the binding-defective D84KTR protein and the fusion-defective L493V protein, when coexpressed. Incubation of cell lysates from the single transfections of wildtype or L493V proteins with the R-peptide antiserum immunoprecipitated their p15E subunits, as expected (Fig. 4A, lanes  2 and 3) . R-peptide antiserum could not immunoprecipitate the p12E subunit of D84KTR (lane 4) when it was transfected a Supernatant from transfected GPL cells was applied to 3 ϫ 10 4 NIH 3T3 cells in six-well plates with Polybrene (8 g/ml), followed by a 10-day selection in G418 (0.5 mg/ml). G418-resistant colonies were counted after methylene blue staining (n ϭ 3, mean Ϯ standard error).
by itself, although this TM protein could be immunoprecipitated through its interaction with SU by an anti-gp70 antiserum (Fig. 4B, lane 4) . In contrast, the coexpression of D84KTR with the full-length wild-type or the L493V envelope protein allowed this truncated p12E to be precipitated by the anti-Rpeptide antiserum (Fig. 4A, lanes 5 and 6) , indicating the formation of heterooligomers.
Stoichiometry of complementation. We next examined the stoichiometry of the interaction between functional binding and fusion domains in the envelope protein complex. If we model the MoMuLV envelope oligomer as a trimer as postulated (8, 9) , there may be an advantage to having, for example, two normal binding domains (and one normal fusion domain) versus two normal fusion domains (and one normal binding domain). To examine this question, we repeated the cotransfection assay with different ratios of D84KTR and L493V plasmid DNA and analyzed the levels of syncytium formation obtained. The maximum syncytium formation occurred at a D84KTR-to-L493V plasmid DNA molar ratio of 10:1 (Fig. 5) , suggesting that the functional species has a greater requirement for wild-type fusion domains than for binding domains.
DISCUSSION
Data from this study indicate that binding-defective (SU) and fusion-defective (TM) mutants of the oligomeric envelope protein of MoMuLV can functionally complement each other in trans. This complementation could result from one of two possibilities, either an interaction between monomers within a single heterooligomer unit or an interaction between different homooligomers on the viral surface. Several lines of evidence support the former conclusion.
Cleavage of the TM subunit of MoMuLV envelope protein by the viral proteinase removes the C-terminal 16 amino acids (the R peptide) and produces an envelope protein that is more fusogenic than the full-length protein and can cause syncytium formation when expressed on NIH 3T3 cells (25, 27) . The fact that only the R-peptide-truncated form of MoMuLV envelope protein can cause syncytia in NIH 3T3-based cell lines pro- D84KTR ϩ dl603-606.......................................................... 
.... ϩϩ
a Envelope protein expression plasmids were transfected or cotransfected (at a ratio of 1:1) into GPL cells, and the cells with more than four nuclei were scored as syncytia under the microscope ϩϩϩϩ, massive syncytium formation observed in the CEETR transfection (Fig. 3) ; ϩϩϩ, ϩϩ, and ϩ, approximately 80, 50, and 10% of the CEETR value, respectively; Ϫ, no syncytia.
b CEETR and D84KTR are R-peptide-truncated forms of wild-type CEE vided us with a tool to study the interaction of monomers within the envelope protein complex.
We initially observed that the coexpression of a truncated form of an SU binding mutant, D84KTR, with the full-length wild-type envelope protein on NIH 3T3 cells resulted in the formation of syncytia. The mechanism of action of R-peptide cleavage is unknown, but it is possible that it leads to a change in the conformation of the ectodomain of the protein (30) . We hypothesized that the activation of the envelope protein through R-peptide cleavage is likely to occur only within the same envelope protein oligomer. In support of this hypothesis, we further noted that D84KTR could activate syncytium formation when coexpressed with the various full-length TM mutants and that there was a degree of heterogeneity in the extent of the syncytia that resulted. All of the TM mutants (which provided the functional SU subunit) were able to bind to the MoMuLV receptor as well as the wild-type envelope protein did (Table 1) , and their levels of cell surface expression were similar (data not shown). However, the amount of syncytium formation resulting from their coexpression with D84KTR varied considerably (for example, compare L493V with L493R [ Fig. 3 , Table 3 ]), although the functional TM domain, provided by D84KTR, was constant. This suggested that the fusion functions were not provided solely by a homooligomer consisting only of the functional D84KTR TM subunit but were provided as part of a mixed (and therefore partially defective) fusion unit and that there was variation in the severity of the fusion defect among the different TM mutants.
Additional evidence for the functional unit being a heterooligomer was provided by the rescue of the transport-and binding-defective mutant E/A. It seems unlikely that the defect in transport to the cell surface of this mutant could be rescued without the formation of a complex with normally transported envelope protein molecules. Within such a heterooligomer, the binding defect of this protein was rescued by the wild-type binding domains of the TM mutants. Finally, we demonstrated by coimmunoprecipitation that heterooligomers between D84KTR and a TM mutant, L493V, were physically present.
The analysis of the stoichiometry of complementation produced an optimal ratio of 10:1 for syncytium formation when D84KTR and L493V were coexpressed. Clearly, more functional TM subunits than SU-binding domains are required. In a simple model, with the MoMuLV envelope protein oligomer presumed to be a trimer, this suggests that the functional heterooligomer contains two monomers of D84KTR and one monomer of L493V. In this scenario, the observed ratio of 10:1 is higher than expected for the optimal production of such 2:1 heterooligomers. However, it is possible that once an initial binding event has occurred (which may itself only require one functional receptor binding site per oligomer), additional oligomers are recruited into a fusion pore and triggered to a fusogenic state in the absence of a direct interaction of the SU subunits with a receptor. The trans-dominant phenotype reported for N-terminal TM mutants of human immunodeficiency virus type 1 may reflect the fact that more than one functional oligomer is probably needed to create a fusion pore (10) . In addition, this simple model does not consider the possibility that certain of the oligomeric species actually inhibit syncytium formation, which would skew the ratio. In particular, the presence of homooligomers of L493V, which would bind nonproductively to receptors, could be detrimental by sequestering receptors on the cell surface. Also, we cannot exclude the fact that the amount of DNA used in the ratio study may not correlate with the level of protein expressed on the cell surface. Finally, it is also possible that the MoMuLV envelope protein complex is a tetramer or higher-order structure.
Our results provide evidence that monomers of the MoMuLV envelope protein cooperate within the envelope protein complex, with functional complementation possible in trans between the SU and TM subunits of different monomers. Furthermore, we have demonstrated that an envelope protein complex can be functional if there is a normal binding domain and a normal fusion domain within the envelope oligomer, even when no single monomer is capable of carrying out both binding and fusion. We suggest that these findings explain the requirement for the coexpression of wild-type envelope protein to obtain functional targetable envelope proteins, as reported by other workers (5, 13, 19, 29) . It remains to be determined in these situations whether the wild-type envelope is complementing function at the level of transport, incorporation into virions, or in the postbinding events that lead to fusion, since our data suggest that complementation of function is possible at each of these stages.
One of the challenges to engineering retroviral envelope proteins to achieve targeted gene delivery is to reproduce the presumed postbinding changes that lead to the formation of a fusogenic protein. If binding and fusion functions can be contributed by different subunits of an oligomer and if the fusion functions contributed by TM can be activated without the interaction of its cognate SU subunit with receptor, it seems feasible to design targeting complexes in which the targeting ligand can function in trans with respect to the protein providing the fusion functions.
